BlueWillow Biologics

BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of Michigan, employs novel oil-in-water nano-droplets as an intranasal adjuvant that elicits a robust mucosal and balanced Th1/Th2 systemic immune response. This NanoVax® platform has established proof of concept in humans and enables intranasal vaccines for challenging respiratory infections, sexually transmitted infections and food allergies. The company’s lead candidates include intranasal vaccines for Covid-19, HSV-2, Peanut Allergy, RSV, Anthrax and pandemic influenza.